While miR-23a and -23b have not been described elsewhere to target human or rodent Ndrg2, miR-28-5p was reported recently to target and suppress human NDRG2 in chronic lymphocytic leukemia cells [46]. Here, NDRG2 is linked to B-cell chronic lymphocytic leukemia.